← Back to Clinical Trials
Recruiting NCT05322837

NCT05322837 Tracking of Upper Limb Sensory and Motor Recovery in Asian Stroke Survivors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05322837
Status Recruiting
Phase
Sponsor Tan Tock Seng Hospital
Condition Stroke
Study Type OBSERVATIONAL
Enrollment 400 participants
Start Date 2023-04-26
Primary Completion 2026-01

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 90 Years
Study Type OBSERVATIONAL
Interventions
Clinical and technological-aided assessments and questionnaires

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 400 participants in total. It began in 2023-04-26 with a primary completion date of 2026-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

As Singapore's population is aging rapidly, the incidence rate of stroke has been increasing in the past years. Rehabilitation is essential for the resumption of daily activities, and with the appropriate care, it is possible for stroke-survivors to regain most of their functions. Hence, this study aims to better understand upper limb recovery covering different stages post-stroke in a representative cohort of Asian adults

Eligibility Criteria

Inclusion Criteria: 1. Stroke confirmed by neurologists, neurosurgeons and brain imaging (CT, CT angiogram, MRI, MR angiogram) 2. First ever confirmed stroke 3. Asian ethnicity 4. Age 21-90 years 5. Montreal Cognitive Assessment (MOCA) scores 21/30 and above 6. Admission to rehabilitation ward is within 8 weeks of stroke onset Exclusion Criteria: 1. Recurrent stroke or transient ischaemic attack (TIA) 2. Upper limb impairment not related to stroke: e.g., subarachnoid haemorrhage, traumatic brain injury or brain tumours 3. Bilateral upper limb impairment. 4. Uncontrolled medical conditions such as hypertension, hypotension, diabetes mellitus, unstable angina, cardiac failure or sepsis will be excluded. 5. Active fractures or arthritis of upper limb joints/bones 6. Visual Analogue Scale (VAS) pain \> 5/10 7. MOCA \< 21/30 8. Severe behavioural disturbance or agitation or epilepsy or untreated depression 9. Life expectancy \< 6 months 10. End organ failures on replacements (renal dialysis or renal replacement therapies) 11. Minimally responsive or unresponsive awareness (vegetative) states 12. Pregnancy or lactation states 13. Admission to rehab ward later than 8 weeks post-stroke 14. (For TMS assessments only) History of epilepsy or seizures, or cranial surgeries, or have metal implants in body or head, or have implanted electronics, or have metallic valve, or skull fracture or brain injury, or head or brain surgeries.

Contact & Investigator

Central Contact

Megan Lau Si En

✉ Megan_SE_Lau@ttsh.com.sg

📞 68894580

Principal Investigator

Dr Karen Chua, MBBS

PRINCIPAL INVESTIGATOR

Tan Tock Seng Hospital

Frequently Asked Questions

Who can join the NCT05322837 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 90 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05322837 currently recruiting?

Yes, NCT05322837 is actively recruiting participants. Contact the research team at Megan_SE_Lau@ttsh.com.sg for enrollment information.

Where is the NCT05322837 trial being conducted?

This trial is being conducted at Singapore, Singapore.

Who is sponsoring the NCT05322837 clinical trial?

NCT05322837 is sponsored by Tan Tock Seng Hospital. The principal investigator is Dr Karen Chua, MBBS at Tan Tock Seng Hospital. The trial plans to enroll 400 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology